Effectiveness of BNT162b2 Vaccine Booster against SARS-CoV-2 Infection and Breakthrough Complications, Israel

We estimated vaccine effectiveness (VE) of the BNT162b2 (Pfizer-BioNTech, https://www.pfizer.com) booster dose against SARS-CoV-2 infection and reduction of complications (hospitalization, severe disease, and death) among breakthrough cases in persons in Israel >16 years of age for <20 weeks....

Descripción completa

Detalles Bibliográficos
Autores principales: Glatman-Freedman, Aharona, Bromberg, Michal, Hershkovitz, Yael, Sefty, Hanna, Kaufman, Zalman, Dichtiar, Rita, Keinan-Boker, Lital
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Centers for Disease Control and Prevention 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9045419/
https://www.ncbi.nlm.nih.gov/pubmed/35361311
http://dx.doi.org/10.3201/eid2805.220141

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9045419/
https://www.ncbi.nlm.nih.gov/pubmed/35361311
http://dx.doi.org/10.3201/eid2805.220141

Ejemplares similares